The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity

The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart failure in patients with high-risk type 2 diabetes. Recently, the CANVAS program also showed that canagliflozin, another SGLT2 inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ningning, Rahman, Asadur, Hitomi, Hirofumi, Nishiyama, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070601/
https://www.ncbi.nlm.nih.gov/pubmed/30093883
http://dx.doi.org/10.3389/fendo.2018.00421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070601/
https://www.ncbi.nlm.nih.gov/pubmed/30093883
http://dx.doi.org/10.3389/fendo.2018.00421

Ejemplares similares